Zhijie Yin1, Jinbo Gao1, Weizhen Liu1, Cheng Huang1, Xiaoming Shuai1, Guobin Wang1, Kaixiong Tao1, Peng Zhang2. 1. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China. 2. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei Province, China. zhangpengwh@hust.edu.cn.
Abstract
OBJECTIVES: The objectives of this paper were to investigate the clinicopathological characteristics and prognostic factors of GI-bleeding GIST patients and explore whether GI bleeding is a risk factor for GIST relapse. METHODS: Primary GIST patients with initial symptoms of GI bleeding or no GI bleeding were retrospectively studied. RESULTS: Up to 178 GI-bleeding GIST patients including 108 (60.7%) males and 70 (39.3%) females were evaluated for the clinicopathological characteristics. The stomach, small bowel, and colorectum were the tumor sites in 82 (46.1%), 85 (47.8%), and 11 (6.2%) patients. Of the 178 patients, 163 GI-bleeding patients had follow-up while another 363 patients from the total population presented without GI bleeding were followed up. Up to 526 patients who received postoperative follow-up were included in the survival analysis. Compared with the 363 non-GI-bleeding patients, GI-bleeding patients developed smaller tumors (P = 0.015) and had a longer relapse-free survival (RFS; P = 0.014). For the 163 GI-bleeding patients, a Cox regression analysis showed that the mitotic count and the platelet-lymphocyte ratio before surgery were independent prognostic predictors for poor outcome regarding RFS. For all 526 patients, a Cox regression analysis indicated that tumor location, mitotic index, platelet-lymphocyte ratio, and GI bleeding were independent prognosis predictors. CONCLUSION: Compared to non-GI-bleeding GIST patients, patients with GI bleeding were more likely to be male and to have more small intestine GISTs, smaller tumors, and a longer RFS. For GI-bleeding patients, mitotic count and platelet-lymphocyte ratio were independent prognostic indicators. GI bleeding served as a surrogate for smaller GIST and was a protective factor for GIST recurrence.
OBJECTIVES: The objectives of this paper were to investigate the clinicopathological characteristics and prognostic factors of GI-bleeding GISTpatients and explore whether GI bleeding is a risk factor for GIST relapse. METHODS: Primary GISTpatients with initial symptoms of GI bleeding or no GI bleeding were retrospectively studied. RESULTS: Up to 178 GI-bleeding GISTpatients including 108 (60.7%) males and 70 (39.3%) females were evaluated for the clinicopathological characteristics. The stomach, small bowel, and colorectum were the tumor sites in 82 (46.1%), 85 (47.8%), and 11 (6.2%) patients. Of the 178 patients, 163 GI-bleedingpatients had follow-up while another 363 patients from the total population presented without GI bleeding were followed up. Up to 526 patients who received postoperative follow-up were included in the survival analysis. Compared with the 363 non-GI-bleedingpatients, GI-bleedingpatients developed smaller tumors (P = 0.015) and had a longer relapse-free survival (RFS; P = 0.014). For the 163 GI-bleedingpatients, a Cox regression analysis showed that the mitotic count and the platelet-lymphocyte ratio before surgery were independent prognostic predictors for poor outcome regarding RFS. For all 526 patients, a Cox regression analysis indicated that tumor location, mitotic index, platelet-lymphocyte ratio, and GI bleeding were independent prognosis predictors. CONCLUSION: Compared to non-GI-bleeding GISTpatients, patients with GI bleeding were more likely to be male and to have more small intestine GISTs, smaller tumors, and a longer RFS. For GI-bleedingpatients, mitotic count and platelet-lymphocyte ratio were independent prognostic indicators. GI bleeding served as a surrogate for smaller GIST and was a protective factor for GIST recurrence.
Authors: Arnoud J Templeton; Olga Ace; Mairéad G McNamara; Mustafa Al-Mubarak; Francisco E Vera-Badillo; Thomas Hermanns; Boštjan Seruga; Alberto Ocaña; Ian F Tannock; Eitan Amir Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-03 Impact factor: 4.254
Authors: C C Xiao; S Zhang; M H Wang; L Y Huang; P Wu; Y Xu; X L Zhu; W Q Sheng; C Y Du; Y Q Shi; Z Q Guan; S J Cai; G X Cai Journal: J Gastrointest Surg Date: 2013-01-04 Impact factor: 3.452
Authors: Danielle A Bischof; Yuhree Kim; Ramy Behman; Paul J Karanicolas; Fayez A Quereshy; Dan G Blazer; Shishir K Maithel; T Clark Gamblin; Todd W Bauer; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2014-09-23 Impact factor: 3.452
Authors: Hariti Saluja; Christos S Karapetis; Susanne K Pedersen; Graeme P Young; Erin L Symonds Journal: Front Oncol Date: 2018-07-24 Impact factor: 6.244